Regional Entrepreneurial Opportunities in the Biotech Industry: Exploring the Transition from Award-winning Nascent Entrepreneurs to Real Start-ups
Claus Michelsen, H. Wolf, Michael Schwartz
European Planning Studies,
2013
Abstract
Welche Faktoren beeinflussen maßgeblich die Wahrscheinlichkeit, dass potenzielle bzw. werdende Unternehmensgründer (nascent entrepreneurs) ihre Gründungsabsicht tatsächlich umsetzen? Hierüber ist bislang kaum etwas bekannt. Das Wissen um die zentralen Einflussfaktoren ist jedoch von hoher Relevanz für die Ausgestaltung eines wirtschaftspolitischen Förderinstrumentariums. Existierende Studien legen einen Fokus auf personenspezifische Merkmale, lassen jedoch die regionale Komponente weitgehend unberücksichtigt. Ausgehend von der Annahme, dass Entrepreneurship stark ortsgebunden stattfindet, argumentiert der Beitrag, dass die Triebkräfte des Übergangs von nascent entrepreneurs zur faktischen Unternehmensgründung in regionalen Rahmenbedingungen (regional entrepreneurial opportunities) zu suchen sind. Diese Annahme wird anhand eines Datensatzes von 103 werdenden Gründern der deutschen Biotechnologiebranche empirisch überprüft. Dabei wird zugleich ein neues Maß der Erfassung von nascent entrepreneurs eingeführt. Dieses umfasst Akteure, die aktiv an einem oder mehreren Gründerwettbewerben teilgenommen haben und in mindestens einem Fall als Preisträger daraus hervorgegangen sind (award-winning nascent entrepreneurs). Unter Berücksichtigung technologischer und personenspezifischer Faktoren bestätigt das ökonometrische Modell in hohem Maße die aufgestellten Hypothesen. Demnach wird die Wahrscheinlichkeit, vom potenziellen zum tatsächlichen Gründer zu werden, stark von allgemeinen wie auch spezifischen regionalen Rahmenbedingungen beeinflusst. Zudem kann der Einfluss einer regionalen Gründerkultur bzw. eines positiven Gründerklimas auf die Übergangswahrscheinlichkeit nachgewiesen werden.
Read article
Regional Entrepreneurial Opportunities in the Biotech Industry: Exploring the Transition from Award-winning Nascent Entrepreneurs to Real Start-ups
H. Wolf, Claus Michelsen, Michael Schwartz
Abstract
Knowledge of factors that determine the transition from nascent entrepreneurship into real entrepreneurship is of major importance for policies aiming to effectively stimulate start-ups. Whereas scholars concentrated on person-specific factors to explain transition probabilities, environmental characteristics have been fairly neglected. Given that entrepreneurship is a strongly localized phenomenon, this paper argues that regional entrepreneurial opportunities are a driving force behind the transition from nascent entrepreneurship to new venture creation. Based on unique data on 103 nascent entrepreneurs in the German biotechnology industry, we empirically assess the importance of regional entrepreneurial opportunities on transition probabilities. Further, we introduce a new
approach to measure nascent entrepreneurship by capturing individuals that actively participate in start-up competitions and have won at least one competition. Controlling for technology and individual characteristics, we find strong support for our hypotheses relating to the significant impact of general regional opportunities, specific regional opportunities and the entrepreneurial environment for the probability of transition from award-winning nascent entrepreneurs to real start-ups.
Read article
Consequences, opportunities and challenges for modern biotechnology for Europe (BIO4EU) - TASK 2. Report 3
S. Gaisser, Iciar Dominguez Lacasa, Thomas Reiss
Einzelveröffentlichungen,
No. 4,
2008
Abstract
Modern biotechnology is one of the key enabling technologies of the 21st century with a potentially wide range of applications in many sectors, including health, agriculture and industrial processes. Considering the potential of modern biotechnology to contribute to the achievement of major European Union policy goals, such as economic growth and job creation, public health, environmental protection and sustainable development, the European Parliament has requested the European Commission to carry out an assessment of modern biotechnology. The European Commission welcomed the initiative and announced to undertake a study “to conduct a cost benefit analysis of biotechnology and genetic engineering, including genetically modified organisms in the light of major European policy goals formulated in the Lisbon Strategy,
Read article
Exploring technological change in the German pharmaceutical industry. Dissertation
Iciar Dominguez Lacasa
Einzelveröffentlichungen,
No. 2,
2006
Abstract
In simple words the pharmaceutical industry links activities and business accomplishing the discovery, development, production and commercialisation of drugs (i. e. products with therapeutic properties). Accordingly, product innovation is based on the search and development of molecules that may have desirable therapeutic effects. Basically new drugs can be developed either with the application of organic chemical synthesis or from the separation of compounds produced by natural microorganisms, which as an application of biotechnology.
Read article
Performance of European countries in biotechnology - How does Europe compare to the USA?
Thomas Reiss, Iciar Dominguez Lacasa
International Journal of Biotechnology Vol. 10 (4),
2008
Abstract
Read article
Bridging the biotechnology gap: policy experiences from the Czech Republic, Estonia, Hungary and Slovenia.
Iciar Dominguez Lacasa
International Journal of Biotechnology Vol. 10 (4),
2008
Abstract
Read article
Inventory and analysis of national public policies that stimulate research in biotechnology, its exploitation and commercialisation by industry in Europe in the period 2002–2005.
C. Enzing, A. van der Guissen, Sander van der Molen
Luxembourg: Office for Official Publications of the European Communities,
2007
Abstract
Read article
Inventory and analysis of national public policies that stimulate biotechnology research, its exploitation and commercialisation by industry in Europe in the period 2002–2005: Final Report
Inventory and analysis of national public policies that stimulate research in biotechnology, its exploitation and commercialisation by industry in Europe in the period 2002–2005,
2007
Abstract
Read article
Benchmarking national biotechnology policy across Europe: a systems approach using quantitative and qualitative indicators.
Thomas Reiss, Iciar Dominguez Lacasa
Research Evaluation. Special issue on new challenges in quantitative science and technology research Vol. 16 (4),
No. 4,
2007
Abstract
Read article
Capturing the changes in the knowledge base underlying drug discovery and development in the 20th century and the adjustment of Bayer, Hoechst, Schering AG and E. Merck to the advent of modern biotechnology.
Iciar Dominguez Lacasa
Scientometrics,
No. 2,
2006
Abstract
Read article
